Table 5 ADCs for BTKi-resistant MCL
Drug or Combination | Targets | Study (size) | Outcomes | Adverse events | CT identifier (Ref) |
|---|---|---|---|---|---|
Zilovertamab vedotin (VLS 101) | ROR-1 | R/R Phase 1 (15) | ORR 47% | Fatigue, Diarrhea, contusion | NCT03833180 |
Denintuzumab mafodotin (SGN-CD19A) | CD19 | R/R Phase 1 | No results posted | – | NCT01786135 |
Loncastuximab Tesirine (ADCT-402) | CD19 | R/R Phase 1 (18) | ORR-47% CR-33.3% PR-13.3% PFS-4.8 months | Fatigue, edema, liver enzyme abnormalities | NCT02669017 [202] |
Inotuzumab ozogamicin + R-GDP | CD22 | R/R Phase 1 (13) | ORR-62% | Thrombocytopenia, neutropenia | NCT01055496 [204] |
SGN-CD70A | CD70 | R/R Phase 1 (5) | – | Thrombocytopenia, Fatigue, Anemia | NCT02216890 [205] |
Polatuzumab vedotin + venetoclax + rituximab | CD79b | R/R Phase 2 (63) | Recruiting | – | NCT04659044 |
Polatuzumab vedotin + mosunetuzumab | CD79b and CD3/CD20 | R/R Phase 1/2 | Active, not recruiting | – | NCT03671018 |
AGS67E | CD37 | Phase 1 (2) | ORR-22% | – | NCT02175433 [203] |